Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06343272

Lymphocyte Enhancement in Gastroenteric Oncology

Effects of a Supplementation With a Mixture of Essential Amino Acids on Enhancing the Number of Circulating Lymphocytes and Improveing the Tolerance to Chemotherapy Treatment in Patients With Advanced Gastroinmtestinal Malignances the LEGO Trial

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
54 (estimated)
Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

LEGO is single center double-blind randomized trial aimed at testing the efficacy of an essential ammino acid (EAA) supplementation in improving the absolute count of peripheral lymphocytes and the tolerance to chemotherapy in patients with advanced gastrointestinal malignancies not candidates to immune check-point inhibitors containing regimens.

Detailed description

The aim of the study is to verify that, in lymphopenic patients, AAE supplementation leads to an increase in lymphocytes circulating in the blood. In particular, at the end of treatment, in patients with lymphocytes \< 29.7% of the total number of white blood cells, we want to observe the disappearance of lymphopenia.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTEAA supplementationThe experimental group will receive the mixture (Amino-Ther® PRO, Professional Dietetics, Milan) composed of (in mg): L-leucine 1200, l L-isine 900, L-threonine 700, L-isoleucine 600, L-valine 600, L-cystine 150, L histidine 150, L-phenylalanine 100, L-methionine 50, L-tryptophan 50, vitamin B6 0.85, vitamin B1 0.70, citric acid 409, acidomalic 102.5, succinic acid 102.5. 1 sachet dissolved in 150 ml of water at 10.00 am +1 sachet at 4.00 pm daily for 60 days There are: proteins 0.00 g, carbohydrates 2.1 g, fats 0.00 g
OTHERIsocaloric placeboThe control group will take 25g of maltodextrins daily with the same methods as the treated group: 1 sachet dissolved in 150 ml of water at 10.00 am +1 sachet at 4.00 pm daily for 60 days

Timeline

Start date
2022-03-22
Primary completion
2024-12-22
Completion
2025-02-28
First posted
2024-04-02
Last updated
2024-04-03

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT06343272. Inclusion in this directory is not an endorsement.